API Board unanimously concludes Wesfarmers proposal is "not compelling".

Australian Pharmaceutical Industries has just announced the rejection of the indicative proposal from Wesfarmers Limited, which had offered $1.38 per share to acquire 100% of the company.

The API Board said it had unanimously concluded that the offer "undervalues API, is not compelling and is not in the best interests of API shareholders".

The company cited Wesfarmer's "opportunistic timing" given the impact that COVID and the related lockdown restrictions have had on API's financial performance over the last 18 months, and particularly on its retail facing businesses.

More details in today's issue of Pharmacy Daily.

advertimg.png

This Pharmacy Daily breaking news is brought to you by  JPH Group

To ensure you continue to receive email from Pharmacy Daily reliably please add info@pharmacydaily.com.au to your 'Safe Senders' list and set images to always display.

To forward this email to a friend click here.  To receive your own copy of Pharmacy Daily sign up here.
To modify subscription details click here.  To unsubscribe click here.

facebook.com/pharmacydaily  Follow us on Instagram  PD on LinkedIn  Follow us on Twitter  Pharmacy Daily TV  PD on Google+

The Therapeutic Goods Advertising Code 2015 requires strict compliance. View the code here.

Pharmacy Daily - a division of Business Publishing Group
PO Box 1010 Epping NSW Australia 1710
Level 2, Suite 1 64 Talavera Rd Macquarie Park NSW 2113